EXCLUSIVE: Adial Pharmaceuticals' Last Patient Dosed in Pharmacokinetics Study of AD04 For Alcohol Use Disorder, Data Expected In Q4
Portfolio Pulse from Vandana Singh
Adial Pharmaceuticals (NASDAQ:ADIL) announced the completion of dosing in the pharmacokinetics study of AD04 for Alcohol Use Disorder. The study's topline results are expected in Q4 2024, marking a significant milestone towards initiating Phase 3 clinical trials.
August 07, 2024 | 12:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Adial Pharmaceuticals has completed dosing in the pharmacokinetics study of AD04 for Alcohol Use Disorder. This milestone is crucial for the initiation of Phase 3 clinical trials, with topline results expected in Q4 2024.
The completion of dosing in the pharmacokinetics study is a significant milestone for Adial Pharmaceuticals, indicating progress towards Phase 3 clinical trials. The anticipation of topline results in Q4 2024 could generate positive sentiment among investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100